Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives $41.17 Average PT from Analysts

Key Points

• Kiniksa Pharmaceuticals International has received a consensus rating of "Buy" from six analysts, with an average 12-month price target of $41.17.
• Insider sales have been significant, with insiders selling 544,971 shares valued at $18.2 million in the last ninety days, indicating a potential decrease in confidence among company leadership.
• The company reported strong quarterly earnings, beating estimates with a net revenue of $156.8 million and earnings per share of $0.23, surpassing the projected $0.18.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has been given a consensus rating of "Buy" by the six research firms that are presently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $41.1667.

KNSA has been the subject of a number of recent research reports. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Finally, Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 7th.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA traded down $0.50 during trading hours on Monday, hitting $35.42. The company's stock had a trading volume of 489,203 shares, compared to its average volume of 386,927. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $37.34. The company's 50 day simple moving average is $32.62 and its two-hundred day simple moving average is $27.61. The company has a market cap of $2.62 billion, a P/E ratio of 885.72 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The company had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 16,400 shares of the business's stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $36.46, for a total transaction of $597,944.00. Following the completion of the transaction, the chief operating officer directly owned 34,552 shares in the company, valued at approximately $1,259,765.92. The trade was a 32.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Michael R. Megna sold 11,000 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total value of $383,240.00. Following the transaction, the chief accounting officer owned 38,011 shares of the company's stock, valued at approximately $1,324,303.24. This trade represents a 22.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 561,371 shares of company stock valued at $18,825,009. 53.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KNSA. Northern Trust Corp raised its holdings in shares of Kiniksa Pharmaceuticals International by 11.1% during the 4th quarter. Northern Trust Corp now owns 283,599 shares of the company's stock worth $5,610,000 after acquiring an additional 28,393 shares in the last quarter. Bank of America Corp DE increased its position in shares of Kiniksa Pharmaceuticals International by 2.2% during the 4th quarter. Bank of America Corp DE now owns 215,772 shares of the company's stock valued at $4,268,000 after purchasing an additional 4,654 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $256,000. Deutsche Bank AG increased its position in shares of Kiniksa Pharmaceuticals International by 77.3% during the 4th quarter. Deutsche Bank AG now owns 142,397 shares of the company's stock valued at $2,817,000 after purchasing an additional 62,083 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $61,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.